What is the most frequent type of thyroid cancer in females?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 13, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Most Frequent Thyroid Cancer in Females

Papillary thyroid cancer is the most frequent type of thyroid cancer in females, accounting for approximately 80% of all thyroid cancer cases.

Epidemiology and Incidence

According to the ESMO Clinical Practice Guidelines, papillary thyroid cancer has an incidence of 8.8 per 100,000 woman-years compared to only 1.06 per 100,000 woman-years for follicular thyroid cancer 1. The incidence rates for papillary thyroid cancer are significantly higher among women than men, with women having a rate that is more than three times higher than men (8.8 vs 2.7 per 100,000 person-years) 1.

The NCCN Guidelines further support this, indicating that of all thyroid carcinoma cases:

  • 80% are papillary carcinoma
  • 11% are follicular carcinoma
  • 3% are Hürthle cell carcinoma
  • 4% are medullary carcinoma
  • 2% are anaplastic thyroid carcinoma 1

More recent data from 2015 shows that among patients diagnosed with thyroid carcinoma between 2008 and 2012, the distribution was:

  • 89% papillary carcinoma
  • 5.1% follicular carcinoma
  • 2.2% Hürthle cell carcinoma
  • 1.7% medullary carcinoma
  • 0.8% anaplastic thyroid carcinoma 1

Gender Differences and Risk Factors

Thyroid cancer occurs 2 to 3 times more often in women than in men 1. It is currently the fourth most common malignancy diagnosed in women 1. The peak incidence of thyroid cancer in women is around 45-49 years of age, compared to 65-69 years in men 1.

Among women, papillary thyroid cancer incidence rates vary by ethnicity:

  • Higher among Asians (10.96 per 100,000 woman-years)
  • Lower among blacks (4.9 per 100,000 woman-years) 1

Prognosis

Papillary thyroid cancer generally has an excellent prognosis:

  • 10-year survival rates exceed 90% 2
  • 10-year relative survival rate for papillary carcinoma is 93% 1

This is significantly better than the prognosis for anaplastic thyroid carcinoma, which has a 5-year relative survival rate of only about 7% 1.

Clinical Implications

The high prevalence of papillary thyroid cancer in females has important implications for screening and early detection. The increasing incidence of thyroid cancer over recent decades is primarily due to increased detection of small papillary carcinomas through improved diagnostic techniques such as neck ultrasound and fine needle aspiration cytology 1.

Nearly 60-80% of thyroid carcinomas detected nowadays are micropapillary thyroid carcinomas (<1 cm in size), which carry an excellent long-term prognosis 1.

Understanding that papillary thyroid cancer is the most common type in females helps guide appropriate diagnostic and treatment approaches, including surgical management, radioactive iodine therapy, and TSH suppression with thyroid hormone replacement.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.